Search Results - "Jouary, T"

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Guidelines for the management of vitiligo: the European Dermatology Forum consensus by Taieb, A., Alomar, A., Böhm, M., Dell'Anna, M.L., De Pase, A., Eleftheriadou, V., Ezzedine, K., Gauthier, Y., Gawkrodger, D.J., Jouary, T., Leone, G., Moretti, S., Nieuweboer-Krobotova, L., Olsson, M.J., Parsad, D., Passeron, T., Tanew, A., van der Veen, W., van Geel, N., Whitton, M., Wolkerstorfer, A., Picardo, M.

“…Summary The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now,…”
Get full text

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study by Jouary, T., Leyral, C., Dreno, B., Doussau, A., Sassolas, B., Beylot-Barry, M., Renaud-Vilmer, C., Guillot, B., Bernard, P., Lok, C., Bedane, C., Cambazard, F., Misery, L., Estève, E., Dalac, S., Machet, L., Grange, F., Young, P., Granel-Brocard, F., Truchetet, F., Vergier, B., Delaunay, M.M., Grob, J.J.

“…The treatment of stage I Merkel cell carcinoma (MCC) usually includes wide local excision (WLE) combined with irradiation of the tumor bed (ITB). No randomized…”
Get full text

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial by Leyvraz, S., Piperno-Neumann, S., Suciu, S., Baurain, J.F., Zdzienicki, M., Testori, A., Marshall, E., Scheulen, M., Jouary, T., Negrier, S., Vermorken, J.B., Kaempgen, E., Durando, X., Schadendorf, D., Gurunath, R. Karra, Keilholz, U.

“…In uveal melanoma (UM) with metastatic disease limited to the liver, the effect of an intrahepatic treatment on survival is unknown. We investigated…”
Get full text

Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure by Belin, E., Ezzedine, K., Stanislas, S., Lalanne, N., Beylot-Barry, M., Taieb, A., Vergier, B., Jouary, T.

“…Summary Background  Primary eccrine porocarcinoma is a rare cutaneous neoplasm and there is no consensus concerning its surgical management. Objectives  To…”
Get full text

DRESS syndrome with pustules and cardiac impairment by Messagier, A-L, Salzes, C, Jouary, T

“…An original case of DRESS syndrome is reported herein with a particular cutaneous presentation and etiology. A 52-year-old man developed a febrile pustular…”
Get full text

Inflammasome activation and vitiligo/nonsegmental vitiligo progression by Marie, J., Kovacs, D., Pain, C., Jouary, T., Cota, C., Vergier, B., Picardo, M., Taieb, A., Ezzedine, K., Cario-André, M.

“…Summary Background Polymorphisms of NLR (nucleotide‐binding domain and leucine rich repeat containing) family, pyrin domain containing protein 1 (NLRP1) have…”
Get full text

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas by Toulemonde, E., Chevret, S., Battistella, M., Neidhardt, E. M., Nardin, C., Le Du, F., Meyer, N., Véron, M., Gambotti, L., Lamrani-Ghaouti, A., Jamme, P., Chaffaut, C., De Pontville, M., Saada-Bouzid, E., Beylot-Barry, M., Simon, C., Jouary, T., Marabelle, A., Mortier, L.

“…Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus…”
Get full text

Living with vitiligo: results from a national survey indicate differences between skin phototypes by Ezzedine, K., Grimes, P.E., Meurant, J.-M., Seneschal, J., Léauté-Labrèze, C., Ballanger, F., Jouary, T., Taïeb, C., Taïeb, A.

Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre by Kostopoulou, P., Jouary, T., Quintard, B., Ezzedine, K., Marques, S., Boutchnei, S., Taieb, A.

“…Summary Background  Vitiligo affects around 0·5% of the population. The burden of disease perceived by patients seems to be underestimated by the medical…”
Get full text

Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms by Gey, A., Diallo, A., Seneschal, J., Léauté-Labrèze, C., Boralevi, F., Jouary, T., Taieb, A., Ezzedine, K.

“…Summary Background  Vitiligo/nonsegmental vitiligo (NSV) is often associated with thyroid dysimmunity although very few reports have studied this association…”
Get full text

Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? by Gey, A., Milpied, B., Dutriaux, C., Mateus, C., Robert, C., Perro, G., Taieb, A., Ezzedine, K., Jouary, T.

Get full text

French updated recommendations in Stage I to III melanoma treatment and management by Guillot, B., Dalac, S., Denis, M.G., Dupuy, A., Emile, J.F., De La Fouchardiere, A., Hindie, E., Jouary, T., Lassau, N., Mirabel, X., Piperno Neumann, S., De Raucourt, S., Vanwijck, R.

“…As knowledge continues to develop, regular updates are necessary concerning recommendations for practice. The recommendations for the management of melanoma…”
Get full text

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma by Le Tourneau, C, Dreno, B, Kirova, Y, Grob, J J, Jouary, T, Dutriaux, C, Thomas, L, Lebbé, C, Mortier, L, Saiag, P, Avril, M F, Maubec, E, Joly, P, Bey, P, Cosset, J M, Sun, J S, Asselain, B, Devun, F, Marty, M E, Dutreix, M

“…Background: DT01 is a DNA-repair inhibitor preventing recruitment of DNA-repair enzymes at damage sites. Safety, pharmacokinetics and preliminary efficacy…”
Get full text

Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo by Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Seneschal, J., Boniface, K., Cario-André, M., Prey, S., Ballanger, F., Boralevi, F., Jouary, T., Mossalayi, D., Taieb, A.

“…Summary Background  Limited epidemiological data exist that compare clinical features of pre‐ and post‐pubertal nonsegmental vitiligo. Objectives  To compare…”
Get full text

Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo by Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Séneschal, J., Prey, S., Ballanger, F., Alghamdi, K., Cario-André, M., Jouary, T., Gauthier, Y., Taieb, A.

“…Summary Background  Until now, segmental vitiligo has been considered as a stable entity and mixed vitiligo, the association of segmental and nonsegmental…”
Get full text

New guidelines for stage III melanoma (the French Cutaneous Oncology Group) by Guillot, B, Dupuy, A, Pracht, M, Jeudy, G, Hindie, E, Desmedt, E, Jouary, T, Leccia, M-T

“…Improved knowledge of sentinel node procedures coupled with the results of adjuvant clinical trials in stage III melanoma have prompted the French Cutaneous…”
Get full text

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma by Mourah, S., Porcher, R., Battistella, M., Kerob, D., Guillot, B., Jouary, T., Agbalika, F., Morinet, F., Furlan, V., Teisserenc, H.M., Dupin, N., Lebbé, C.

Get full text

Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients by Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Mossalayi, D., Gauthier, Y., Bouchtnei, S., Cario-André, M., Seneschal, J., Boralevi, F., Jouary, T., Taieb, A.

“…Summary Background  Although mixed forms have been described recently, segmental (SV) and nonsegmental vitiligo (NSV) are considered as clinically distinct…”
Get full text